Recruiting nowPhase 3All ages

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Sponsor: University of Utah · NCT03422198 on ClinicalTrials.gov ↗

Conditions studied

Endometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous AdenocarcinomaStage I Uterine Corpus CancerStage IA Uterine Corpus CancerStage IB Uterine Corpus CancerStage II Uterine Corpus CancerUterine Corpus CarcinosarcomaUterine Corpus Sarcoma

What it tests

Vaginal Cuff Brachytherapyradiation
Short course vaginal cuff brachytherapyradiation

Where it's running5 sites

Stanford Cancer Center
Palo Alto, California 94304
Completed
Loyola University Medical Center
Maywood, Illinois 60153
Recruiting now
- Carly Quick, RN(contact)708-327-3255 [email protected]
- Lorena Leon(contact)464-220-9395 [email protected]
- William Small, MD(principal investigator)
MD Anderson
Houston, Texas 77030
Recruiting now
- Mathew G Geena(contact)713-792-4594 [email protected]
- Anuja Jhingran, MD(principal investigator)
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
Recruiting now
- Rachel Kingsford(contact)801-585-0115 [email protected]
- Cristina DeCesaris, MD(principal investigator)
Intermountain Medical Center / LDS Hospital
Salt Lake City, Utah 84143
Completed

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:

  * Stage IA, grade 1 with LVSI, 2, 3
  * Stage IB, grades 1-3
  * Stage II, grades 1-3
  * Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.
* Participants post-hysterectomy and free from residual disease.
* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2.
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
* Life expectancy of \>2 years.

Exclusion Criteria:

* Stages of endometrial carcinoma other than described.
* Previous pelvic radiotherapy.
* Concurrent malignancy requiring non-protocol anti-cancer treatment other than surgery.

Updated 2025-12-12 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.